Journal: International Journal of Molecular Sciences

Article Title: Reduced Percentage of CD14 dim CD16 + SLAN + Monocytes Producing TNF and IL-12 as an Immunological Sign of CLL Progression

doi: 10.3390/ijms23063029

Figure Lengend Snippet: Percentage of classical (CD14 + CD16 − SLAN − ), intermediate (CD14 + CD16 + SLAN − ) and non-classical monocytes (CD14 dim CD16 + SLAN + ) assessed for intracellular expression IL-10, TNF and IL-12 in “ex vivo” conditions. The solid line marks the median value. Ɪ represents the interquartile range (IQR).

Article Snippet: Cells prepared in this way were incubated with monoclonal antibodies: Mouse Anti-Human TNF PE (clone: MAb11, Cat.No 559321, BD Biosciences), Mouse Anti-Human IL-12 PE (p40/p70) (clone: C11.5, Cat No. 559329, BD Biosciences) and Rat Anti-Human IL-10 PE (clone: JES3-19F1, Cat. No. 559330, BD Biosciences).

Techniques: Expressing, Ex Vivo

Journal: International Journal of Molecular Sciences

Article Title: Reduced Percentage of CD14 dim CD16 + SLAN + Monocytes Producing TNF and IL-12 as an Immunological Sign of CLL Progression

doi: 10.3390/ijms23063029

Figure Lengend Snippet: Expression of IL-10, TNF and IL-12 at the mRNA level in classical (CD14 + CD16 − SLAN − ), intermediate (CD14 + CD16 + SLAN − ) and non-classical monocytes (CD14 dim CD16 + SLAN + ) in ex vivo conditions in 20 randomly selected CLL patients.

Article Snippet: Cells prepared in this way were incubated with monoclonal antibodies: Mouse Anti-Human TNF PE (clone: MAb11, Cat.No 559321, BD Biosciences), Mouse Anti-Human IL-12 PE (p40/p70) (clone: C11.5, Cat No. 559329, BD Biosciences) and Rat Anti-Human IL-10 PE (clone: JES3-19F1, Cat. No. 559330, BD Biosciences).

Techniques: Expressing, Ex Vivo

Journal: International immunology

Article Title: Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

doi: 10.1093/intimm/dxl046

Figure Lengend Snippet: Fig. 4. IL-18 is required for induction of IFN-c by TLR-7/8 agonists in human PBMC. PBMC, pre-incubated for 1 h with neutralizing antibodies specific for TNF-a, IL-12p40/70, IFN-a/bR, IL-18 or IL-10, were stimulated overnight with poly I:C at 25 lg ml1, 3M-001-3 at 3 lM or ssRNA40 at 2.5 lg ml1 (0.4 lM) for comparison with vehicle control (DOTAP + dimethyl sulfoxide). Total secreted IFN-c (A) or IL-18 (B) was measured at 24 h. Means and SEM values from four experiments are shown. Control antibody indicates functional grade mIgG1 control. Additional control antibodies including mIgG2a, rtIgG1 and rtIgG2a tested in separate experiments showed <15% reduction in IFN-c levels (data not shown). (C) Histogram overlays display IFN-c expression by NK cells in 3M-003- or ssRNA40-treated PBMC cultures (line) relative to control vehicle treatments (solid gray). The proportion of IFN-c-positive NK cells relative to vehicle controls at 24 h is indicated. Representative data from three experiments are shown. (D) Next, PBMCs were pre-incubated for 1 h with control antibody, anti-IL-12p70, anti-IL-18 or the combination of anti-IL-12p70 together with anti-IL-18 followed by stimulation with 3M-002 (3 lM) or ssRNA40 [2.5 lg ml1 (0.4 lM)]. Secreted IFN-c was measured at 24 h.

Article Snippet: Neutralizing antibodies, anti-tumor necrosis factor (TNF)-a (mAb1, mIgG1) and anti-IL-12p40/70 (C8.6, mIgG1) were obtained from eBioscience; anti-IL-12p70 (24910, mIgG1) was obtained from R&D systems (Minneapolis, MN, USA); anti-IL-18 (125-2H, mIgG1) was obtained from Medical & Biological Laboratories Co., Ltd, (MBL; Naka-ku Nagoya, Japan) and anti-IL-10 (JES3-9D7, rtIgG1) was obtained from BD Biosciences.

Techniques: Incubation, Comparison, Control, Functional Assay, Expressing